Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Bulls and Bears 1

News

Markets

AMZN

ENPH

INTC

NFLX

NVAX

RKLB

SMMT

TMUS

TSLA

Benzinga examined the prospects for many investors&#39; favorite stocks over the last week — here&#39;s a look at some of our top stories.

Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back

Medical,Research,And,Development,Center:,Female,Asian,Scientist,Using,Microscope

Biotech

Health Care

Movers

Trading Ideas

General

BNTX

NAVX

Novavax&#39;s COVID-19 vaccine showed fewer side effects than Pfizer&#39;s in a Utah study as FDA seeks more data before full approval decision.

Novavax&#39;s COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps

Konskie,,Poland,-,January,16,,2024:,Amphenol,Company,Logo,Displayed

Intraday Update

EWBC

GTLS

HCSG

HOOD

LITE

NVDA

PEGA

PONY

PSIX

SMCI

SMTC

Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday

Novavax Inc

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million

Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza

Contracts

Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone

Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025

Earnings

Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Novavax to Participate in Upcoming March Investor Conferences

Novavax Announces Changes to Board of Directors

SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

CAPC

Ardelyx

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Geron

GRAIL

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

MiMedx Group

Mesoblast Limited - American Depositary Shares

Mesoblast

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

MannKind

Nurix Therapeutics

Arcus Biosciences

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

HC Wainwright & Co.

Jefferies

B. Riley Securities

JP Morgan

B of A Securities

Comments

Novavax

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell